Dr. Guo Shanshan, research assistant professor and a Shenzhen High-Level Talent (Pengcheng Peacock Plan, Class C). She earned her bachelor's degree from Huazhong University of Science and Technology, pursued her master's and doctoral studies at the National Center for Nanoscience and Technology, completed joint doctoral training at the QIMR Berghofer Medical Research Institute in Australia, and subsequently worked as a postdoctoral researcher and assistant researcher at the Amsterdam University Medical Center and the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. Her primary research focuses on the pathophysiological mechanisms of metabolic diseases and the exploration of therapeutic strategies. Relevant findings have been published in journals such as Nano Letters,Blood,Haematologica,ACS Applied Materials & Interfaces, and Molecular Metabolism.She has secured project funding from the China Postdoctoral Science Foundation and the Guangdong Basic and Applied Basic Research Foundation, etc. Since January 2024, she has served as a Young Editorial Board Member of Nano TransMed.

Education Background

2015-2019, University of Chinese Academy of Sciences, PhD, Supervisor: Nie Guangjun;

2015-2017, QIMR Berghofer Medical Research Institute, Australia, Joint PhD Training, Supervisor: Greg Anderson;

2012-2015, University of Chinese Academy of Sciences, Master's, Supervisor: Nie Guangjun;

2008-2012, Huazhong University of Science and Technology, School of Life Science and Technology, Base Class (Bioinformatics Direction), Bachelor;

Professional Experience

2024-Present, Shenzhen University of Advanced Technology, research assistant professor;

2023-2024, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, assistant researcher;

2021-2023, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Postdoctoral Researcher, Co-supervisor: Zhou Bing;

2019-2021, Amsterdam University Medical Center, Netherlands, Postdoctoral Researcher, Co-supervisor: Chun-Xia Yi;

Research Projects

1. China Postdoctoral Science Foundation General Grant, 2022-2023, completed, principal investigator

2. Guangdong Basic and Applied Research Fund - Yue-Shen Joint Youth Fund Project, 2022-2025, ongoing, principal investigator

3. Guangdong Youth Innovation Talents Program for Regular Higher Education Institutions Higher Education, 2024-2026, ongoing, principal investigator

4. Shenzhen Medical ResearchFund, General Category, Frontier Exploration, B2402001, 2025-2027, ongoing, participant

Representative Achievements

1.Guo S, Yi C.X. Cell type-targeting nanoparticles in treating central nervous system diseases: Challenges and hopes.Nanotechnology Reviews2023. 12(1), 20230158.

2.Guo S,Cázarez‐Márquez F, Jiao H, et al. Specific silencing of microglial gene expression in the rat brain by nanoparticle-based siRNA delivery.ACS Applied Materials & Interfaces2022. 14(4): 5066–5079.(This work was previewed by Matter, 2022, 5(8): 2529-2530.)

3.Guo S, Liu G, Frazer D.M,et al. Polymeric nanoparticles enhance the ability of deferoxamine to deplete hepatic and systemic iron.Nano Letters2018.18(9): 5782-5790.

4. Lu B,Guo S, Zhao J, et al. Adipose knockout of H-ferritin improves energy metabolism in mice.Molecular Metabolism2024.101871.

5. Liu G,Guo S, Anderson G.J., et al. Heterozygous missense mutations in the GLRX5 gene cause sideroblastic anemia in a Chinese patient.Blood2014.124(17):2750-1.

6. Liu G,Guo S, Kang H, et al. Mutation spectrum in Chinese patients affected by congenital sideroblastic anemia and a search for a genotype-phenotype relationship.Haematologica2013.98(12):e158-60.

7.Guo S, Frazer D.M., Anderson G.J. Iron homeostasis: transport, metabolism, and regulation.Current Opinion in Clinical Nutrition and Metabolic care2016.19(4):276-81.

8.Guo S, Wang L, Li X, et al. Identification of a novel UROS mutation in a Chinese patient affected by congenital erythropoietic porphyria.Blood Cells, Molecules & Diseases2014. 52(1):57-8.

9. Guo Shanshan, Liu Gang, Nie Guangjun. Iron and Human Health: Chapter 10: Erythroid Iron Metabolism. Science Press. 2014.

10. You L, Wang J, Liu T, Zhang Y, Han X,Wang T, Guo S, et al. Targeted Brain Delivery of Rabies Virus Glycoprotein 29-Modified Deferoxamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Mice.ACS Nano2018. 12(5): 4123-4139.

11. Wang Y, Du Y, Liu G, Guo S, Yang N, Hou B,et al.Contiguous gene deletion in HFE2 region (1q21. 1) and pathogenic HFE2 mutations in a Chinese hereditary hemochromatosis patient.Gene Reports2016. 5, 167-170.

12. Wang Y, Du Y, Liu G, Guo S, Hou B, Jiang X,et al. Identification of novel mutations in HFE, HFE2, TfR2, and SLC40A1 genes in Chinese patients affected by hereditary hemochromatosis.International journal of hematology2017.105(4), 521-525.

Authorized International and Domestic Patents

1.Nie Guangjun,Guo Shanshan, Liu Gang. An Iron Chelator-Encapsulating Amphiphilic Polymer Nanoparticles: Preparation Methods and Applications. Patent Number: 2015102055699.X.

1.Pathophysiology of iron metabolism-related diseases;

2.Application of liver and brain targeting strategies;

3.Exploring and Applying Novel Nanomedicine-Based Therapeutic Strategies for Metabolic Diseases.